Progress on FY08 Workplan Activities

	Activity	Staff Lead	Progress	Indicators	Impact	Remarks
			Q1			
Common Agenda						
Objective:	***Support global health initiatives by providing up-to-date information about current issues in drug quality and appropriate use.***					
Activity 1.	Maintain and update the DQI website.	**M Foster**	Added 24 new articles, 21 photos, 40 DI updates; updated 3 existing web pages and 3 AI reports; added or updated 3 resource materials	# new articles added; # new or updated resources added; # pages updated		
Activity 2.	Update and promote the *Matrix of Drug Quality Reports Affecting USAID-assisted Countries*	**M McGinnis**	Updated Matrix with 23 new reports; 4,403 website hits	# of reports added; # of website hits	increased awareness of up-to-date substandard/ counterfeit drug situation	Beginning Feb 2009, Matrix will be updated monthly
Objective:	***Stimulate the interest of stakeholders in drug quality work.***	**P Lukulay**				
Activity 1.	Attend and participate in international conferences on drug quality and present at at least one confeence.		GDF conference in Rio de Jeneiro planned in March. Will present GMP templtes prepared for manufacturers.	Conferences identified for FY 09; presentations made		
Objective:	***Build institutional competencies to support the appropriate management and use of pharmaceuticals***	**A Barojas**				
Activity 1.	Produce-Learning course on drug quality.		Course content has undergone minor internal & USAID reviews and revisions.	Obtain DQI staff approval; Obtain CTO approval; Obtain USAID E-Learning Center approval	USAID staff and other stakeholders will have an introductory course freely available on the internet to on issues related to drug quality and how to assure the quality of medicines, focusing on developing country context.	The course material is currently being finalized and will be distributed for entire DQI staff and CTO review. This is estimated to occur in Feb 09. After incorporating CTO comments & approval the material will be transferred to the online server. The course will then need to be reviewed by the USAID E-Learning Center Manager. Once approved in this last step it will go live to the public. This will occur Q2-Q3.
Activity 2.	Supplement USA D Country Mission funds for continuation of QAMSA.		Samples from Madagascar Senegal, and Uganda have been received at USP/Rockville. Confirmatory testing of more than 200 products from these samples are in progress. Testing is completed for approximately one-third of these products.	Samples shipped to USP/Rockville lab; Samples tested and data reviewed; findings documented; report disseminated		
Activity 3.	Conduct a assessment of DRA and NQCL in Zambia.			Assessment plan developed and approved; on-site assessment conducted; report disseminated to stakeholders; draft workplan submitted to CTO		Statement of Work (SoW) to be devleoped and sent to USAID Zambia mission in Q2.
P.E. 3.1.2	**Tuberculosis (TB)**	**P. Lukulay**				
Objective: (3.1.2.1)	***Strengthen implementation of DOTS expansion and enhancement through standards development and guidelines.***					
Objective: (3.1.2.4)	***Reduce the spread of MDR- and XDR-TB through better access to second-line treatment.***					
Activity 1.	Provide technical assistance to manufacturers tof second-line TB medicines seeking to obtain WHO prequalification.		Kilitch Dossier accepted by WHO for detailed review. Planned face to face meeting to review WHO comments	# dossier submitted to WHO. # of companies prequalified		
Activity 2.	Conduct activities related to GDF programs.		DQI director went to Geneva to develop a priority list of second line TB medicines and companies to receive technical assistance. Eight new manufacturers have been contacted and informed about DQI TA. Awaiting responses.			
Activity 3.	Develop pharmacopeial monographs for second-line TB drugs.		Contacts have been made with two companies in India.	Two medicines selected; two monographs developed		
P.E. 3.1.3	**Malaria**	**M. Hajjou**				
Objective: (3.1.3.0)	***Promote cooperation on drug quality issues through a Drug Quality Monitoring network.***					
Activity 1.	Develop a network of drug quality monitoring countries in Africa (Senegal, Uganda, Ghana, Ethiopia and Madagascar).		Contacts with countries are being made and venue for first workshop has been determined.	Network established and functional; Member-identification wksp conducted; guidance document produced and disseminated to members; data-sharing documented		
Objective: (3.1.3.6)	***Support multi-country study of the quality of ACTs and SPs in PMI-supported countries***					

Progress on FY08 Workplan Activities

Activity 2.	Support Senegal and Uganda in conducting confirmatory testing.		Training has been completed and Minilab testing by the USP-supported countries has been completed. Confirmatory testing of more than 200 products from these countries is in progress at USP/Rockville lab.	Training conducted; confirmatory testing done in all USP-supported countries; report generated and disseminated		
Objective: (3.1.3.1)	***Develop pharmacopeial monograph for an ACT drug.***					
Activity 3.	Develop pharmacopeial monographs for key anti-malarial medicines.		Manufacturers have been identified for priority antimalarials and contacts are being made in conjunction with USP Standards Acquisition Department to solicit for analytical data to develop these monographs	Mfr identified and contacted; comparative testing completed and reported; quality specs documented; monograph drafted for public comment; monograph published in SALMOUS		
P.E. 3.1.4	**Avian Influenza**	**S Phanouvong**				
Objective: (3.1.4.1)	***Plan and Prepared for Outbreak Response***					
Activity 1.	Test oseltamivir samples as needed.		compendial methods under final review	# samples tested	Ensure and maintain the quality of oseltamivir products from manufacture and acquisition to use	
Activity 2.	Produce quality specifications for oseltamivir.		2 content sections added (out of 7 total): 1. "quality characteristics of API" and 2. "quality characteristics of finished dosage forms"	One document developed in collaboration with partners		technical guidelines directed at govt and non-govt agencies for procurement, distribution, etc for ensuring quality of oseltamivir products
P.E. 3.1.6	**Maternal Health and Child Survival**	**E Toledo**				
Objective: (3.1.6.6)	***Prevent and treat childhood diarrheal illness***					
Activity 1.	Conduct quality control/GMP assessment of zinc manufacturers for global and local supply		Performed GMP audit on Shelys and Zenufa; reports disseminated			
Activity 2.	Develop two additional pharmacopoeia monographs on zinc (acetate and gluconate formulations).		Zinc Gluconate monograpgh drafted and put in PF. Will be published late in 2009. Zinc Acetate monograpgh-contacts being sought.	Each monograph received and validated	Reduce cost of zinc by increasing local capacity for production and improving procurement of good quality zinc products by UNICEF and other procurement orgs	
Activity 3.	Conduct drug quality testing of zinc samples submitted by UNICEF, USAID Missions, and partners.			Number of samples tested and results (goal=40); report presented to appropriate stakeholders		Nutriset and Square signed a contract with UNICEF for 2008 zinc tender requesting zinc sulfate samples from Indonesia; samples on the way;
Objective: (3.1.6.2)	***Improve newborn health outcomes***					
Activity 1.	Conduct Quality Control/GMP assessment of a chlorhexidine manufacturer (Lomus Pharmaceutical Nepal) for global and local supply.		GMP assessment conducted in January and corrective actions being drafted	GMP assessments successfully conducted, reports presented to stakeholders		
Objective: (3.1.6.5)	***Improving coverage and supplementation of vitamin A for children under 5***					
Activity 1.	Develop pharmacopeial monographs for Vitamin A Gelcaps as requested by USA D.		Monograph drafted and put in PF for review	Monograph received and validated.		

	Activity	Staff Lead	Progress	Indicators	Impact	Remarks
			Q1			
Benin		**M Hajjou**				
Objective:	***Obtain data on antimalarial medicines through a country monitoring program***					
Activity 1.	Conduct Assessment of drug quality control capabilities in Benin.		Completed	Participate in mtg; assessment conducted; report delivered; work plan developed and approved by USAID/Mission		
Activity 2.	Provide basic supplies for medicines quality monitoring program.		Activity cancelled	Lab materials provided		
Activity 3.	Train staff in medicines quality monitoring methods.		Activity on hold	NDQCL staff trained		
Activity 4.	Organize one collaborative study on antimalarial drug quality.		Planned	Samples collected and tested; report shared with stakeholders; recommendations made		
Ethiopia		**P Lukulay/K Smine**				
Objective:	***Establish and support a postmarketing drug quality monitoring program***					
Activity 1.	Develop Antimalarial Postmarketing Surveillance strategy.		Microplanning workshop conducted and strategy for drug quality monitoring established	Partnership and coordination among stakeholders strengthened; available documents re: antimalarial DQM reviewed and approaches discussed; workplan developed and agreed upon		
Activity 2.	Develop training materials and train staff.		Training conducted for 15 staff	Sampling protocol developed; training materials prepared; sentinel sites identified; # staff trained; following agreed-upon protocol		
Activity 3.	Organize Postmarketing Surveillance - Round I (Phase 1)		Sampling done and Minilab testing completed. Confirmatory testing done and data under review	# samples purchased at identified sites; # Minilab analyses performed and validated		
Activity 4.	Organize Postmarketing Surveillance - Round I (Phase 2)			Samples purchased; confirmatory testing completed and findings analyzed		
Activity 5.	Disseminate results in media and raise awareness.			Report presented and disseminated; geo-referencing complete; follow-up action taken (as appropriate)		
Activity 6.	Organize Postmarketing Surveillance - Round II (Phase 2)			Confirmatory testing completed; analysis completed		
Activity 7.	Report findings to stakeholders.			Report completed and presented		
Ghana		**P Lukulay/K Smine**				
Objective:	***Establish and support a postmarketing drug quality monitoring program***					
Activity 1.	Develop implementation plan, study design and protocol.		Implementation plan developed and sentinel sites selected	Implementation plan agreed upon; 5-7 sites identified; sampling protocol developed		
Activity 2.	Procure GPHF Minilabs.		5 Minilabs procured	5 Minilabs, replacement reagents, and training materials purchased		
Activity 3.	Train FDB and NMCP staffs.		Training planned for Feb	2 analysts per site trained in sampling procedures and use of Minilab		
Activity 4.	Conduct two rounds of sampling and testing.			Samples of antimalarials, TB and HIV/AIDS medicines purchased; confirmatory testing completed and reported		

Activity 5.	Follow up on Actitivies 1-4.			Findings shared with appropriate stakeholders; govt action sought as appropriate		
Objective:	***Conduct an assessment of NQCL capability to conduct confirmatory QC testing***					
Activity 1.	Assess and service equipment used for QC testing and conduct training.			Equipment assessed, serviced and operational		
Activity 2.	Train in confirmatory testing as neccessary.			2 FDB chemists trained		
Liberia		**L El Hadri**				
Objective:	***Support the LMRC in developing comprehensive national drug legislation and in building a drug quality assurance system***					
Activity 1.	Provide technical assistance to the LMRC to finalize draft legislation relating to quality assurance issues and submit to parliament		In-country assessment for QA/QC completed; a visit is planned for Feb to finalize legislation draft	Meeting held; draft legislation reviewed; recommendations provided; legislation in progress		
Objective:	***Develop a framework for the establishment of a national medicines quality control laboratory***					
Activity 1.	Support Liberia Ministry of Health in pursuing establishment of a national medicines quality control laboratory		Study of cost of establishing a QC lab is ongiong	Proposal submitted; TA provided		
Madagascar		**M Hajjou**				
Objective:	***Support the established drug quality monitoring/postmarketing program***					
Activity 1.	Continue to support antimalarial drug quality monitoring.		Minilab procured for the new sentinel site. Resources provided to carry out 1 round of sampling and testing	Sentinel sites identified and operational, Minilab provided; supplies in-country; samples taken; testing completed; report presented to stakeholders		
Objective:	***Finalize the QAMSA Study in Madagascar***					
Activity 1.	Finalize QAMSA Study		Confirmatory testing completed for 12 samples	Samples selected and tested; report updated		
Objective:	***Strengthen the pharmacovigilance program in Madagascar***					
Activity 1.	Strengthen National Pharmacovigilance		300 health professionals received training in PV in 6 districts	Regional focal points provide training; ADEs reported to the PV center		
Objective:	***Support the newly established Drug Information Center***					
Activity 1.	Support the Drug Information Center.		Resources provided	Reference books purchased; newsletter issued		
Mali		**M Hajjou**				
Objective:	***Strengthen drug quality control capacity of National QC Lab (LNS)***					
Activity 1.	Procure needed equipment, reagents and reference standards.		Planned	Priority drugs selected; lab equipped with necessary material		
Activity 2.	Provide training in GLP and quality control testing methods.		Planned	Staff trained; procedures established		
Activity 3.	Provide training to LNS staff on UV, IR and quality systems.		Planned	Staff trained; at least 50% of quality systems in place		
Objective:	***Monitor and evaluate trainings***					
Activity 1.	Monitor efficiency of DQI training through sampling and testing, and strengthen communications with LNS staff		Activity cancelled	Drugs tested; reports shared		
Objective:	***Help establish a pharmacovigilance program to monitor the safety of ACTs***					
Activity 1.	Assist in establishing a pharmacovigilance program to monitor the safety of ACTs.		Preparation in progress. Workshop tentatively scheduled for May	Workshop conducted and National PV Plan drafted and validated		
Objective:	***Strengthen drug registration in Mali***					
Activity 1.	Arrange for DPM staff to be trained on drug registration by WHO.		Training tentatively scheduled for May	SIAMED software installed; DPM staff trained		
Senegal		**L El Hadri**				
Objective:	***Support the drug quality monitoring program established at sentinel sites***					
Activity 1.	Expand postmarketing drug quality monitoring activities.		Minilab procured for newly identified sentinel site; resources provided to carry out one round of sampling and testing			

Objective:	***Finalize QAMSA Study in Senegal***					
Activity 1.	Complete the QAMSA study in Senegal.		QC testing ongoing at USP lab	Samples selected and tested; report updated		
Objective:	***Continue to support the development of a national pharmacovigilance program***					
Activity 1.	Continue providing technical assistance on the development and implementation of a national pharmacovigilance program in Senegal.		Workshop for launching the natl PV program complete. Training of 2 staff from CAP and DPL is ongoing	Gaps identified; recommendations provided; reporting form developed; training curriculum developed	Establishment of national PV system that governs all PV activities. Senegal will become a full member of WHO international PV program	
Uganda		**L El Hadri**				
Objective:	***Strengthen NDQCL technical capacity to assure the quality control of antimalarial medicines in Uganda***					
Activity 1.	Procure and deliver HPLC system.		ongoing	Equipment installed and working		
Objective:	***Expand and strengthen postmarketing surveillance of antimalarials***					
Activity 1.	Continue to support antimalarial drug quality monitoring.		Minilab procured, resources provided to carry out two rounds of sampling and testing	Sentinel site identified and operational; staff trained; Minilab and supplies in-country; samples taken, testing completed; report presented to stakeholders (for 2 rounds)		
Objective:	***Finalize QAMSA Study in Uganda***					
Activity 1.	Complete the QAMSA study in Uganda.		QC testing is ongoing at USP lab	Test results validated; confirmatory tests completed; report with findings presented to stakeholders		
Objective:	***Strengthen national pharmacovigilance (PV) system***					
Activity 1.	Provide technical assistance to support the National PV Program.		Evaluation of Training for Trainers will be conducted. One month of hands-on training will be provided to one staff of the PV center	Reports reviewed; recommendations provided; training conducted		
Objective:	***Strengthen drug registration***					
Activity 1.	Provide technical assistance to strengthen the drug registration system.		Training on SIAMED software and import verification systems completed for 25 staff from NDA	Staff trained; software used successfully	Improve drug registration process and computerize the import verification system for NDA	

	Activity	Staff Lead	Progress	Indicators	Impact	Remarks
			Q1			
Regional Development Mission/Asia						
RDM/A – Mekong Malaria		**S Phanouvong**				
Objective 1: IR3 & IR5	***Obtain data on antimalarial, selected antibiotic, and HIV/AIDS medicines through a regional monitoring program***					
Activity 1.	Conduct post-marketing surveillance for early detection of poor quality antimalarials to support regulatory actions.		on-going, one round of sampling completed for Laos, and Thailand. Vietnam in progress.	# of samples collected and tested. # of final reports submitted		Thailand and Vietnam completing final reporting and analysis for most recent round of sampling
Activity 2.	Continue to support ANEQAM activities in quality control to countries in the region.		DQI chemists met with USP QA to develop a plan for ISO accreditation for labs we work with in Asia.	QC documentation review completed. ISO 17025 preparation training completed.		Delays due to political instability in Thailand and high level staff changes at Chulalongkorn
Objective 2: IR4 & IR3	***Facilitate national and provincial authorities to support a regional collaborative effort on timely reporting and sharing routinely-collected medicines quality data***					
Activity 1.	Support national and provincial authorities in taking effective action.		initiated preliminary discussions with country partners	SOP that can be adapted to respective country settings; # of investigations conducted; # of regulatory actions, reports and alerts disseminated; # and location of outlets closed, number/type of medicines seized; # of product recalls or withdrawals from the market.		
Activity 2.	Intensify collaboration and data-sharing with relevant partners e.g., WHO-MPACT, INTERPOL and country MRAs in the region for collective action.		Dissemination of relevant data at regional Interpol meeting (Op Storm). One training provided to law enforcement and customs agents (Nov) in Cambodia. In 11 countries, $7 million of counterfeit meds seized, 22 arrests made: data used from DQI for Laos, Cambodia, and Vietnam for Op Storm	# of reports disseminated to partners; # of INTERPOL investigations DQI participates in; # of product recalls or withdrawals from market;# and location of outlets closed; #/type of medicines seized; # of arrests due to INTERPOL investigations using DQI data; # of Interpol enforcement trainings participated in		
Objective 3: IR3	***Raise public awareness about the dangers of counterfeit and substandard medicines***					
Activity 1.	Disseminate public service announcements that USP has filmed and edited through TV and other appropriate means e g. public and professional meetings and websites.		formatting of PSAs and other media for presentation on DQI website, initial contacts with media buying partners for country broadcasts	Number of television broadcasts in Laos, Vietnam and Thailand; number of websites where the PSAs can be downloaded; # of copies made and disseminated; Estimated # of people who saw the PSAs		
Objective 4: IR3	***Complete the quality of antimalarials study in the Cambodia and Thailand cross-border provinces***					
Activity 1.	Complete the study and write up a final report.		first round sample collection and basic testing completed	samples collected from both countries; samples tested at field level; study managed and M&E conducted; 2 progress report; 1 manuscript completed		mid-term review meeting of round one data organized for January, 2009
Objective 5: IR3	***Provide technical assistance to ensure the quality of all anti-malarial medicines to be used in RDM-A funded clinical trials in Thailand and Cambodia***					
Activity 1.	Collect and test antimalarial samples from study investigators or suppliers before (and 8 months thereafter) they are introduced to the USAID/RDM- A supported clinical trials.		USPDQI has notified WHO, USAID and other partners on the availability of this service	1 sampling protocol developed; samples collected and tested.		no formal follow-up requested by clinical trial implementing teams thus far.
RDM/A – Tuberculosis		**S Phanouvong**				
Objective 1: IR3 and IR5	***Obtain data on anti-tuberculosis medicines through a regional monitoring program***					
Activity 1.	Intensify existing mechanisms for early detection of poor-quality anti-tuberculosis medicines to support regulatory actions.		on-going, one round of sampling completed for Laos, and Thailand. Vietnam in progress.	# of samples collected and tested. # of final reports submitted		Thailand and Vietnam completing final reporting and analysis for most recent round of sampling
Activity 2.	Continue to support ANEQAM activities in quality control to countries in the region.		notification and development of activities with ANEQAM partners in progress	# of trainings completed (1 GMP, 1 QC), medicine quality database updated with recent data		Delays due to political instability in Thailand and high level staff changes at Mahidol and Chulalongkorn (ANEQAM)
Objective 2: **IR4 and IR3**	***Facilitate national and provincial authorities to support a regional collaborative effort on timely reporting and sharing of the medicines quality data that is routinely collected***					

Activity 1.	Support national and provincial authorities in taking effective action.		initiated preliminary discussions with country partners	SOP that can be adapted to respective country settings; # of investigations conducted; # of regulatory actions, reports and alerts disseminated; # and location of outlets closed, number/type of medicines seized; # of product recalls or withdrawals from the market.		
Activity 2.	Intensify collaboration and data sharing with relevant partners e.g., WHO-MPACT, INTERPOL and country MRAs in the region for collective action.		Dissemination of relevant data at regional Interpol meeting (Op Storm). One training provided to law enforcement and customs agents (Nov) in Cambodia. In 11 countries, $7 million of counterfeit meds seized, 22 arrests made: data used from DQI for Laos, Cambodia, and Vietnam for Op Storm	# of reports disseminated to partners; # of INTERPOL investigations DQI participates in; # of product recalls or withdrawals from market;# and location of outlets closed; #/type of medicines seized; # of arrests due to INTERPOL investigations using DQI data; # of Interpol enforcement trainings participated in		
RDM/A – Avian Influenza (AI)		**S Phanouvong**				
Objective 1: IR4 and IR5	***Intensify oseltamivir quality monitoring program in the RDM-A region***					
Activity 1.	Intensify existing mechanisms for early detection of poor-quality oseltamivir in the private sector to support regulatory actions.		ongoing	# of samples collected and tested. # of final reports submitted		thus far, circulated oseltamivir products unavailable at sentinel sites.
Objective 2: IR3	***Obtain comprehensive information on the quality of oseltamivir stockpiled in the public sector and on the product's suppliers/distribution network in the region***					
Activity 1.	Obtain and disseminate data on the quality of stockpiled oseltamivir products in the public sector from 4 countries in the Mekong region (Thailand, Vietnam, Cambodia, and Laos for new stocks).		Laos completed one round of sampling, testing, and reporting on stockpiles at central and peripheral sites, as well as WHO stocks. Report disseminated to partners.	oseltamivir testing completed; # countries sampling and testing stockpiled oseltamivir; # of recommendations made for oseltamivir shelf life extension based on compendial testing; # of oseltamivir reference standards acquired and delivered. # of reports on findings to USAID, WHO, MoH		Will collect and test oseltamivir samples in Cambodia and Vietnam Q2-Q3. Oseltamivir monograph being finalized at USP. API bulk reference substance provided by USP for compendial testing in selected countries. Participation in USAID AI partners' meeting, and data presented for Laos and Mekong region.
SEA — Field Support						
	Cambodia	**L Krech**				
Objective 1:	***To improve detection of poor-quality medicines circulating in the Cambodian market***					
Activity 1.	Support existing postmarketing surveillance program, with Department of Drugs and Food (DDF) and National Laboratory for Drug Quality Control (NLDQC).		one round of sampling and basic testing completed. Reagents and supplies procured and delivered to country	Completed 1-2 rounds of sampling and testing; supplies provided; sampling and testing completed; joint visits made; protocol for sampling wholesale markets developed		Global Fund Round 6 and DQI activities will be share costs related to med qual monitoring, lab equip, supplies, and public awareness campaigns
Activity 2.	Strengthen follow-up on findings by national and provincial authorities.			Provided resources for local investigations and additional testing if needed; organized a meeting for data sharing; outcomes communicated to stakeholders		during Q1, sampling and testing was underway, thus no definitive data to follow up on.
Activity 3.	Intensify collaboration and data sharing with relevant partners (e g., WHO-MPACT, Interpol and country MRAs in the region) for collective action.		Cambodia samples delivered from DDF to Interpol via DQI for follow up enforcement action related to Operation Storm. One training completed in Cambodia for Interpol-IMPACT	Attend Interpol and other MRA meetings (at least 2) as appropriate to share data and provide guidance for their investigations. # of enforcement trainings provided to agency partners		
Objective 2:	***Expand and improve pharmacovigilance in Cambodia***					
Activity 1.	Continue to develop the Cambodian Pharmacovigilance Center.		Associate membership in the WHO International Drug Safety Monitoring Program (UMC) attained. 2 newsletters written by the PV center (500 copies to be distributed); initiated proces of procurement of equipment for PV center	Organize trainings for 2 full-time staff members on (i) fundamentals of pharmacovigilance & (ii) hands-on training at a fully functional pharmacovigilance center; Equip the office at the DDF; Develop adverse drug event reporting format and process		PV activities initially targeted at public sector
Objective 3:	***Raise awareness about medicine quality issues and disseminate information among regulators, health care professionals, and the public***					

Activity 1.	Collaborate with Pharmacy Association of Cambodia (PAC) to promote actions against counterfeit medicines.		bulletin published during Q1	PAC bulletins published; filmed interview with His Excellency Yim Yann about counterfeit medicines in Cambodia distributed; copies of interview distributed	Support dissemination of a collection of documents that provide audience-specific information relevant pharmaceutical laws	
Activity 2.	Collaborate with PATH on their TB training curriculum for pharmacists.		met with PATH to discuss implementation strategy for collaborative training in this fiscal year	Participate in 1 training; PATH curriculum reviewed; training module developed		Meetings with PATH to finalize DQI QA/QC quality component to training.
Activity 3.	Distribute Public Service Announcements (PSAs) on the dangers of counterfeit medicines.		developed network of media buying candidates; PSA distributed to USAID, URC, WHO/Thailand, USAID-Camb, and others. PSA shown in 5 separate meetings (local and international)	PSAs are broadcasted on public and private television channels.		500 copies will be made in Feb 09. Meeting with potential distributors in Cambodia Jan 09.
Activity 4.	Produce a short film on how the GPHF Minilab is used to conduct basic quality tests on medicines.		In development phase	Script reviewed; filming completed; film distributed		
Activity 5.	Produce and distribute a regional documentary film on counterfeit medicines.		Activities will begin in Q2	Documentary planned, filmed, edited, and distributed		Meeting with director in Q2.
	Philippines	**L Krech**				
Objective 1:	***Strengthen BFAD activities to provide quality pharmaceuticals, especially for infectious diseases, and maintain postmarketing surveillance of anti-TB medicines***					
Activity 1.	Assist BFAD laboratory to become ISO 17025 accredited.		DQI chemists met with USP QA to develop a plan for ISO accreditation for labs we work with in Asia.	1 training completed; review of BFAD lab SOPs completed; recommendations documented		
Activity 2.	Ensure continued postmarketing surveillance of anti-tuberculosis medicines at the six pilot sites.		Sample collection/testing will start officially in Q2	10 TB medicines collected and tested each month at each of the six sites; supplies in-country; monitoring visits made; TA and training provided as needed; 2 joint site visits made		There have been delays in commencing sampling and testing due to government documents that need to be reviewed and signed. A Project Secretariat was hired locally upon request of the USAID Mission to make sure the study keep progressing and achieves results.

Activity		Staff Lead	Progress	Indicators	Impact	Remarks
			Q1			
Europe and Eurasia						
Russia		**S Phanouvong/K Burimski**				
Objective 1:	***Improve prescribing practices based on proper diagnosis.***					
Activity 1.	Design study to assess impact of the Infectious Diseases Textbook & Distance Learning Program in health facilities in Russia.		Collaborators identified and contract drafted	Collaborators identified; protocol developed; 2 institutions/groups selected; tracer antibiotics selected; ethical clearance obtained		
Activity 2.	Implement study protocol.			DUR of tracer antibiotics conducted; DUR results analyzed; final report developed; study results disseminated; recommendations provided		
Activity 3.	Disseminate results of the study.					
Objective 2:	***Obtain data on the quality of anti-TB medicines in high-TB incidence oblasts in Russia.***					
Activity 1.	Obtain data on quality of anti-TB medicines in selected public and private health facilities, and from manufacturers, distributors/wholesalers and retail outlets in high-TB incidence oblasts in Russia.		Trip completed Dec 2008. Russia FDA contacted to seek permission for Minilab training and screening in Russia	One trip made; sampling protocol adapted and distributed; team and location selected; # samples collected; samples tested; data analyzed; report disseminated		Depending on decisions made by ROSZDRAVNADZOR (Russian FDA), workplan activities may be changed

	Activity	Staff Lead	Progress	Impact	Indicators	Remarks
			Q1			
Amazon Malaria Initiative (AMI)		**V Pribluda**				
Objective: (IR 01)	***Increase evidence-base for LAC PHN priorities***					
Activity 1.	Evaluate and support accessibility and quality of malaria diagnosis and treatment facilities		31 samples of medicines were reported from Guyana; 29 samples passed and two samples failed disintegration tests		Medicines analyzed using basic tests; selected samples confirmed at OMCLs	
Objective: (IR 02)	***Increase knowledge of AMR data among healthcare workers, policymakers and professional societies and inform them of appropriate strategies and interventions to implement***					
Activity 1.	Train health professionals of all levels in diagnosis and in appropriate management and use of antimalarials.					
Objective: (IR 03)	***Better inform policymakers and other stakeholder to use information to ensure implementation of revised policy***					
Activity 1.	Promote and implement evidence-based decision-making on accessibility, quality, and use of appropriate diagnosis and treatment.					
South America Infectious Disease Initiative (SAIDI)		**A Barojas**				
Objective: (IR 01)	***Increased AMR Data/Evidence***					
Activity 1.	Regional: Coordinate drug sampling and testing of antibiotic and anti-TB medicines in Bolivia, Paraguay and Peru.		Coordinated sampling of 15 AB and 5 TB medicines with Bolivia's DRA (UNIMED) and OMCL (CONCAMYT)			
Objective: (IR 02)	***Increase knowledge of AMR data among healthcare workers, policymakers and professional societies and inform them of appropriate strategies and interventions to implement***					
Activity 1.	All participating countries collect and analyze samples; disseminate and evaluate information.		1. Bolivia: Finalized sampling (20 samples, 15 AB & 5 TB) for 3rd round and began testing. 2. Paraguay: CEMIT analyzed 11 AB samples and sent the report to USP DQI for review. 3. Peru: CNCC analyzed 6 AB & TB samples and sent the report to USP DQI for review.	1. Countries have information on the quality of AB and TB medicines 2. Countries have evidence-based data to implement corrective actions 3. Corrective actions are implemented	1. Number of samples collected and analyzed 2. Number of substandard and counterfeit medicines 3. Corrective actions implemented	
Activity 2.	Bolivia: Perform QMS audit in CONCAMYT with participation of CNCC staff.					
Activity 3.	Paraguay: Perform QMS audit in CEMIT with participation of CNCC staff.					
Activity 4.	Paraguay: Strengthen División Nacional de Vigilancia Sanitaria (DNVS, Drug Regulatory Authority).					
Activity 5.	Peru: Provide guidance to CNCC towards ISO 17025 accreditation.		Continuous guidance was provided throughout the 1st Q. On January 2009 CNCC was audited by ACLASS, an intrenationally recognized ANSI-ASQ National Accreditaiton Board company, which recommended CNCC for ISO 17025 accreditation	1. CNCC will operate according to internationally recognized standars ensuring that the data provided by the lab is valid and trustworthy 2. CNCC could be eligible for WHO prequalification 3. CNCC will strengthen its position as a Reference Laboratory for LAC	CNCC receives ISO 17025 accreditation	
Activity 6.	Peru: Strengthen postmarketing surveilance activities in DIRESAs (Regional DRA offices) into SI DIGEMID.		1. Development plan and chronogram of activities for the integration of regional decentralized market surveillance into SI DIGEMID (a web based integrated system at DIGEMID) was received and evaluated. 2. Development initiated	1. Regional market surveillance activities will be integrated into a web based central system 2. Related procedures, activities and tasks will be electronically available	1. Electronic modules for surveillance activities developed 2. DIRESAS surveillance activities integrated into SI DIGEMID	
Activity 7.	Regional: Share results of drug quality with SAIDI partners.					
Objective: (IR 03)	***Improved, more inclusive, and better informed policy making process***					
Activity 1.	Regional: Participate in all SAIDI meetings.					